Loading
A phase 1/2 trial of DS3790a in non-Hodgkin lymphoma, run by Daiichi Sankyo, now recruiting.
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies is a phase 1/2 interventional study registered as NCT07220616 by Daiichi Sankyo, with 420 participants planned, started 2026-01-16 and due to reach its primary completion in 2030-11-30. Interventions recorded: DS3790a and Combination drug.
Shares Daiichi Sankyo, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.